share_log

Ladenburg Thalmann Maintains Buy on United Therapeutics, Raises Price Target to $268

Benzinga ·  Aug 3, 2023 09:28

Ladenburg Thalmann analyst Matthew Kaplan maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $256 to $268.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment